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 Introduction 
 Chronic obstructive pulmonary disease (COPD) is a 
leading cause of chronic morbidity and mortality 
throughout the world. Its prevalence and its social as well 
as economic burden are increasing, due, in part, to the 
aging of the population. According to the global BOLD 
(Burden of Obstructive Lung Disease) study, COPD is 
projected to rank fifth worldwide as cause of death in the 
year 2020  [1] . COPD is related, in many cases but not ex-
clusively, to cigarette smoking, and in some areas of the 
world with large populations, air pollution resulting from 
the burning of biomass fuels has been identified as a rel-
evant risk factor  [2, 3] . 
 Over the past years, the COPD guidelines of various 
national and professional associations have been revised 
 [4–7] and in December 2011, 10 years after its first release, 
the third and updated version of the GOLD (Global Ini-
tiative for Chronic Obstructive Lung Disease) report be-
came available  [8] . Our current guidelines are based on a 
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 Abstract 
The new Swiss Chronic Obstructive Pulmonary Disease 
(COPD) Guidelines are based on a previous version, which 
was published 10 years ago. The Swiss Respiratory Society 
felt the need to update the previous document due to new 
knowledge and novel therapeutic developments about this 
prevalent and important disease. The recommendations 
and statements are based on the available literature, on oth-
er national guidelines and, in particular, on the GOLD (Glob-
al Initiative for Chronic Obstructive Lung Disease) report. Our 
aim is to advise pulmonary physicians, general practitioners 
and other health care workers on the early detection and di-
agnosis, prevention, best symptomatic control, and avoid-
ance of COPD as well as its complications and deterioration.
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previous version, 2002  [9] , and consider new knowledge 
and novel developments. They aim to advise pulmonary 
physicians, general practitioners and other healthcare 
workers on early detection and diagnosis, prevention, 
best symptomatic control, avoidance of complications 
and deterioration of COPD.
 Definition 
 COPD is characterized by chronic airflow limitation 
and a range of pathological changes in the lung, signifi-
cant extrapulmonary effects and important comorbidi-
ties, which may contribute to the severity of the disease 
in individual patients (GOLD, updated 2011)  [8] . The 
chronic airflow limitation is caused by an individual 
mixture of small airway disease (obstructive bronchiol-
itis) and parenchymal destruction (emphysema). Chron-
ic bronchitis is a clinical and epidemiological term and is 
defined by a history of cough and mucus production on 
most days for at least 3 months a year over at least 2 suc-
cessive years. Not all patients with chronic bronchitis 
have COPD, and not all patients with COPD suffer from 
the symptoms of chronic bronchitis.
 Pathophysiology 
 The major risk factors for the development of COPD 
are inhaled toxic substances, particularly tobacco smoke 
and the products from the burning of biomass fuels that 
cause inflammation of the lungs. The inflammation can 
lead to tissue damage if the normal protective and/or re-
pair mechanisms are overwhelmed or defective. The re-
sults of the lung tissue damage are mucus hypersecretion, 
airway narrowing, fibrosis, destruction of the parenchy-
ma and vascular changes. These pathological changes 
lead to airflow limitation, loss of elastic recoil and other 
physiological abnormalities. The inflammation in COPD 
is markedly different from that in asthma. However, 
some patients with COPD also have asthma and the in-
flammation in their lungs may show the characteristics 
of both diseases. Since inflammation is a feature of COPD, 
specific anti-inflammatory therapies may have beneficial 
effects in controlling symptoms, preventing exacerba-
tions and slowing disease progression. However, the re-
sponse of inflammation to corticosteroids in COPD is 
poor, contrary to their effectiveness in asthma.
 Risk Factors 
 COPD arises from an interaction of both host factors 
and environmental exposures. Smoking remains a lead-
ing cause for COPD. It is estimated that in industrialized 
countries, in men about 80% and in women around 60% 
of the COPD mortality is attributable to smoking, where-
as in developing countries smoking contributes to only 
about 45% in men and 20% in women  [10, 11] . In unin-
dustrialized countries biomass fuel utilization for cook-
ing and heating at home is an important environmental 
factor. Other factors may include occupational expo-
sures, passive smoking and outdoor air pollution. The 
population-attributable fraction for the workplace con-
tribution to COPD risk has been estimated to be 15–20% 
in Europe and North America  [10] . The risk in less-regu-
lated areas of the world is likely to be much higher. In the 
SAPALDIA study (Swiss study on Air Pollution And 
Lung Disease in Adults), high levels of occupational ex-
posure to biological dusts, mineral dusts, gases or fumes, 
as determined from self-reports, were found to be associ-
ated with an increased incidence of COPD of GOLD stage 
II or higher  [ 12] .
 Host factors include genetics, epigenetics and other 
characteristics of the host such as bronchial hyperreac-
tivity and a history of asthma  [ 13] as well as a history of 
severe respiratory infection in childhood. Inherited   -1-
antitrypsin deficiency is a single-gene autosomal reces-
sive disease that predisposes to COPD, but this accounts 
for less than 1% of all cases of COPD  [14, 15] . Apart from 
this particular gene, genetic predisposition to COPD is 
very complex and is incompletely understood at present. 
COPD has been associated with the polymorphisms of 
various genes, but very few of these associations have 
been replicated in more than 2 or 3 independent popula-
tion samples  [16] . Other factors may also predispose to 
the development of COPD. Bronchial hyperreactivity is a 
risk factor, even after exclusion of asthmatics  [17, 18] , and 
chronic bronchitis symptoms seem to increase the risk 
for the later development of COPD  [19, 20] .
 Epidemiology and Burden of Disease 
 COPD prevalence data show remarkable variation 
due to differences in survey methods and diagnostic cri-
teria. The BOLD study reports a variability between 
countries in the prevalence of GOLD stage II–IV COPD 
 [21] , ranging from 9% in Iceland to 19% in the Philip-
pines for male subjects of more than 40 years of age. 
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Country-specific age distributions, smoking prevalence 
rates and other important environmental factors may 
contribute to most of these disparities. In Switzerland, in 
a sample of 6,126 subjects (SAPALDIA), the prevalence 
of COPD of GOLD stage II or higher was 5.1% in the 
population aged 30–73 years, and the prevalence of 
GOLD stage I or higher was 10%  [22] . Prevalence was 
strongly dependent on age. Consequently, extrapolated 
to a resident population of 7.8 million in Switzerland 
(2010 census), the estimated number of stage II or higher 
ranges between 200,000 and 300,000, and that for stage 
I or higher is about 400,000.
 Assessment 
 Clinical Assessment 
 Although it is an important part of patient care, phys-
ical examination has a low sensitivity and specificity for 
the detection or exclusion of mild to moderately severe 
forms of COPD. If the physical signs of airflow obstruc-
tion and pulmonary hyperinflation are present, the pa-
tient usually suffers from an advanced stage of the dis-
ease. The leading symptoms of COPD are shortness of 
breath during exercise, exercise limitation and chronic 
cough  [23] . The degree of dyspnea can be assessed by the 
Modified Medical Research Council (mMRC) question-
naire  [24] ( table 1 ). The COPD Assessment Test  [25] has 
a broader coverage of the impact of COPD on the patient’s 
daily life and well-being and correlates closely with health 
status measured using the St. Georges Respiratory ques-
tionnaire. The test has been translated into several lan-
guages, contains 8 items and can be easily performed on 
the internet www.catestonline.org ( table 2 ). Another im-
portant element of a patient’s history is the occurrence 
and frequency of exacerbations. An exacerbation of 
COPD is defined as an acute event characterized by a 
worsening of the patient’s respiratory symptoms that is 
beyond normal day-to-day variations and leads to a 
change in medication. The exacerbation rate varies great-
ly between patients. The best predictor of frequent exac-
erbations ( 6 2 per year) is a history of previous exacerba-
tions and the severity of COPD  [26] . Since COPD often 
develops in middle-aged long-time smokers, patients fre-
quently have a variety of other diseases related to either 
smoking or aging. Comorbidities that occur frequently in 
COPD patients include cardiovascular disease, skeletal 
muscle dysfunction, metabolic syndrome, osteoporosis, 
lung cancer and depression  [27] . The comprehensive as-
sessment of a patient with COPD forms the basis for ther-
apy and combines the symptomatic assessment with the 
patient’s spirometric classification and/or the risk of ex-
acerbations.
 The degree of airflow obstruction, as assessed by the 
FEV 1 , is but one of the essential prognostic features of 
COPD. Several studies have shown that, in addition, the 
severity of dyspnea, walking distance and body mass in-
dex (BMI; see BODE index,  table 3 ) correlate best with life 
expectancy in COPD  [28] .
 Pulmonary Function Testing 
 Lung function should be tested in patients with 
symptoms of COPD such as chronic cough, wheezing, 
shortness of breath and limitation on exertion. Clini-
cians should, however, be alert to the fact that some pa-
tients may deny exercise limitation because they have 
spontaneously reduced their habitual level of activity 
 [29] . Spirometry is the gold standard to assess the pres-
ence and degree of airflow obstruction. The abnormali-
ties consist of a reduction in FEV 1 and in the ratio of 
FEV 1 to the forced vital capacity (FVC). Small, handheld 
spirometers are convenient to use, have a graphic dis-
play, and store and print the numeric results as well as 
the flow-volume curve or the spirogram of the patient. 
Office spirometry should be performed in primary care 
by well-trained personnel  [30, 31] . In COPD, the correla-
tion between peak expiratory flow (PEF) and FEV 1 is 
poor. Therefore, the measurement of PEF, well estab-
lished in the management of asthma, should not be used 
in patients with COPD. The degree of airflow obstruc-
tion in COPD is classified as proposed by the GOLD 
( table 4 ). This arbitrary international staging system is 
intended to standardize the diagnosis of COPD by using 
a fixed threshold of FEV 1 /FVC  ! 0.70 for airflow ob-
struction and to grade its severity based on FEV 1 as per-
cent of predicted (% pred.). However, since the FEV 1 /
Table 1. m MRC scale 
0 No breathlessness, except during strenuous exercise.
1 Shortness of breath when hurrying on the level or walking 
up a slight hill.
2 Walk slower than people of the same age on the level 
because of breathlessness, or have to stop for breath when 
walking at own pace on the level.
3 Stop for breath after walking 100 m or after a few minutes 
on the level.
4 Too breathless to leave the house or breathlessness from 
dressing or undressing.
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FVC ratio declines physiologically with age, using a 
fixed ratio of 0.70 instead of the lower limit of normal 
(LLN), leads to COPD overdiagnosis in older subjects, 
particularly for GOLD stage I. In Switzerland, the SA-
PALDIA study showed that among individuals classi-
fied as GOLD stage I COPD, only the subjects manifest-
ing cough, phlegm or dyspnea had a faster decline in 
FEV 1 , increased respiratory care utilization and im-
paired quality of life. In contrast, asymptomatic indi-
viduals classified as having stage I COPD did not differ 
from subjects with normal lung function  [20] . Thus, for 
subjects with lung function corresponding to GOLD 
stage I, a cautious approach would consider the diagno-
sis of COPD only in those manifesting symptoms of the 
disease. When provided by the spirometer, the use of 
LLN for FEV 1 /FVC is a physiologically sound alterna-
tive which reduces the misclassification of airway ob-
struction  [32–34] . Since in COPD no strong correlation 
exists between the degree of airflow obstruction and 
quality of life, the revised version of GOLD emphasizes 
considering also the severity of shortness of breath and 
the frequency of exacerbations in the assessment of an 
individual patient  [8] .
 Bodyplethysmography is used to measure intrathorac-
ic gas volume for the calculation of residual volume and 
total lung capacity, parameters that reflect pulmonary 
hyperinflation. Diffusing capacity for carbon monoxide 
is measured by the single breath technique. These param-
eters correlate with the degree of emphysema and it is 
therefore recommended that plethysmography is per-
formed on a regular basis for follow-up in patients with 
severe COPD that may benefit from a lung volume reduc-
tion procedure.
Table 2. C OPD Assessment Test
Score
I never cough 1 2 3 4 5 I cough all the time _
I have no phlegm (mucus) in my chest at all 1 2 3 4 5 My chest is completely full of phlegm (mucus) _
My chest does not feel tight at all 1 2 3 4 5 My chest feels very tight _
When I walk up a hill or one flight of stairs 
I am not breathless
1 2 3 4 5 When I walk up a hill or one flight of stairs I am 
very breathless _
I am not limited doing any activities at home 1 2 3 4 5 I am very limited doing activities at home _
I am confident leaving my home despite my 
lung condition
1 2 3 4 5 I am not at all confident leaving my home because 
of my lung condition _
I sleep soundly 1 2 3 4 5 I don’t sleep soundly because of my lung condition _
I have lots of energy 1 2 3 4 5 I have no energy at all _
Total score _
S cores and resulting impact levels: <10 = low; 10–20 = medium; 21–30 = high.
Table 3.  BODE index
Variable B ODE index points
0 1 2 3
FEV1, % pred. ≥65 50–64 36–49 ≤35
Distance walked in 6 min, m ≥350 250–349 150–249 ≤149
mMRC dyspnea scale 0–1 2 3 4
BMI, kg/m2 >21 ≤21
App roximate 4-year survival interpretation: 0–2 = 80%; 3–4 = 
67%; 5–9 = 57%; 7–10 = 18%.
Table 4. G OLD classification of COPD according to the degree of 
airflow limitation based on FEV1 after bronchodilator
GOLD I: mild FEV1 >80% pred.
GOLD II: moderate 50%≤ FEV1 <80% pred.
GOLD III: severe 30%≤ FEV1 <50% pred.
GOLD IV: very severe FEV1 ≤30% pred.
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 Chest X-Ray and Thoracic CT Scan 
 A chest radiograph is indicated as part of the initial 
workup of patients with COPD to exclude concomitant 
pathologies. However, chest films are not sensitive for the 
detection of mild to moderate emphysema. High resolu-
tion computed tomography (HRCT) is the most sensitive 
and specific in vivo technique for the detection, grading 
and morphological characterizing of pulmonary emphy-
sema. While CT scanning is not recommended for rou-
tine clinical assessment of COPD, it may be used to eval-
uate alternative diagnosis and to assess the feasibility of 
lung volume reduction surgery.
 Further Assessment 
 Hypoxemia is an important problem in COPD, accen-
tuates intolerance to physical exercise and adds to its mor-
bidity. Exercise tests such as the 6-minute walk test or, in 
selected cases, spiroegometry should be performed with 
continuous oxygen saturation measurements. If pulsoxym-
etry at rest shows a saturation of  ! 92%, an arterial blood 
gas analysis should be performed. If erythrocytosis is pres-
ent, chronic hypoxemia should be suspected. Measure-
ment of the   -1 antitrypsin serum concentrations is indi-
cated in rapidly deteriorating COPD, in COPD patients of 
below 45 years of age and in cases with emphysema of bas-
al predominance. In the case of increased daytime sleepi-
ness, oximetry at night or respiratory polygraphy may be 
indicated to rule out hypoxemia during sleep or an overlap 
syndrome (COPD and obstructive sleep apnea).
 Our Methodology – A Comment 
 The recommendations and statements in these guide-
lines are based on the available literature, in particular 
the GOLD report  [8] . A level of evidence, i.e. A, B, C or D, 
is indicated when available; these are listed in  table  5 . 
When evidence was lacking or international guidelines 
were conflicting, the authors, elected by the board of the 
Swiss Respiratory Society and representing chest physi-
cians working in private practice, in hospitals and in aca-
demic medicine, reached consensus after appropriate 
discussion.
 Management of COPD 
 Prevention 
 Identification, reduction and control of risk factors 
such as tobacco smoke, occupational exposure and in- 
and outdoor pollution are important steps for preventing 
the development of COPD. Smoking cessation is the sin-
gle most effective intervention with the greatest impact 
on the natural history of COPD  [35, 36] (Evidence A). 
Brief advice by a general practitioner results in smoking 
cessation rates of 7.4%, i.e. an increase of 2.5% over the 
cessation rate in a control group, and counseling of 3–10 
minutes duration achieves higher cessation rates of 
around 12%. With greater investment of time and com-
Table 5. D escription of levels of evidence
Evidence
category
Sources of
evidence
Definition
A Randomized controlled 
trials (RCTs). Rich body 
of data.
Evidence is from end points of well-designed RCTs that provide a consistent pattern of findings 
in the population for which the recommendation is made. Category A therefore requires a 
substantial number of studies involving substantial numbers of participants.
B RCTs. Limited body of 
data.
Evidence is from end points of intervention studies that include only a limited number of 
RCTs, and post hoc, subgroup or meta-analysis of RCTs.
Category B applies when few randomized trials exist, they are small in size and the results are 
somewhat inconsistent, or they were undertaken in a population that differs from the target 
population of the recommendation.
C Nonrandomized trials, 
observational studies
Evidence is from outcomes of uncontrolled or nonrandomized trials or from observational 
studies.
D Panel consensus 
judgment
This category is used only in case the provision of some guidance was deemed valuable, but an 
adequately compelling clinical literature addressing the subject of the recommendation was 
deemed insufficient to justify placement in one of the other categories. The panel consensus is 
based on clinical experience or knowledge that does not meet the above-listed criteria.
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plexity of interventions, including skills training, prob-
lem-solving and psychosocial support, the quit rate can 
reach 20–30% (Evidence A) [37] . In the Lung Health 
Study, a multicenter, controlled clinical trial, a combina-
tion of advice by a physician, group support, skills train-
ing and nicotine replacement therapy achieved quit rates 
of 35% at 1 year and sustained quit rates of 22% at 5 years 
 [38] . Pharmacotherapy is effective in supporting smoking 
cessation attempts and at least one of these substances 
should be prescribed in the absence of contraindications: 
varenicline, bupropion SR and nicotine in various galen-
ic preparations (Evidence A) [39–44] . Occupationally in-
duced respiratory disorders, e.g. in farmers, can be re-
duced or controlled by strategies aimed at reducing the 
burden of inhaled particles and gases at the workplace 
(Evidence B) [45] .
 Patient Education and Self-Management 
 Patient education is effective in accomplishing spe-
cific goals, including smoking cessation  [38] (Evidence 
A), initiating discussion and understanding of advanced 
directives and end-of-life-issues (Evidence B)  [46]  and 
improving patients’ responses to exacerbations (Evi-
dence B) [47] . In addition, elderly patients can benefit 
from interdisciplinary education programs. Individual-
ized, written action plans for patients’ self-management 
improve quality of life and decrease exacerbation recov-
ery time by reducing patients’ delay. Patient education 
accompanied by instruction for self-management and 
individualized, written action plans can improve the 
outcome of exacerbations  [48] . Although there are stud-
ies that show a beneficial effect of disease self-manage-
ment in COPD  [48] , a study with negative results con-
cerning patient’s self-management and COPD-related 
hospitalizations was recently published [49] . Quality as-
sessment in patient instruction and survey by specially 
trained medical staff is therefore crucial.
 Pharmacologic Treatment 
 None of the available medications for COPD is effec-
tive in modifying the long-term progression of airflow 
limitation that is the hallmark of this disease (Evidence 
A). Today’s polypharmacy, overuse and overdose of med-
ications constitute a significant burden on the cost of 
COPD management.
 Bronchodilators 
 Bronchodilator medications are given on either an as-
needed basis or a regular basis to prevent or reduce symp-
toms of COPD (Evidence A). They have the potential to 
improve exhalation, to reduce dynamic hyperinflation, 
to improve exercise performance and to decrease short-
ness of breath. However, they do not modify the decline 
of lung function or, by inference, the prognosis of the dis-
ease (Evidence B). They are given on an as-needed or reg-
ular basis depending on the COPD severity. Inhalation is 
the preferred means of administration. Attention to ef-
fective drug delivery and training in inhalation tech-
nique is essential. The use of metered-dose inhalers 
(MDI) with spacer devices, dry-powder inhalers (DPI) or 
nebulizers should be tailored to the patient’s ability. The 
choice between   2 agonists or anticholinergics or a com-
bination therapy depends on the individual patient re-
sponse in terms of symptom relief and side effects. Long-
acting inhaled bronchodilators are convenient and more 
effective in maintaining symptom relief than short-act-
ing bronchodilators.
 Anticholinergics 
 The inhibition of vagal stimulation of the bronchial 
tree is associated with reduced smooth muscle tone and 
bronchial gland secretion. The bronchodilating effect of 
short-acting inhaled anticholinergics lasts up to 8 h after 
administration (Evidence A). Tiotropium is a long-acting 
anticholinergic bronchodilator, which has to be inhaled 
only once daily  [50] . It reduces exacerbations and related 
hospitalizations, and improves symptoms and health sta-
tus (Evidence A) [51] . In a large, long-term clinical trial 
(UPLIFT)  [52] , there was no effect of tiotropium added to 
other standard therapies on the rate of lung function de-
cline and no reduction in mortality. In another large trial, 
tiotropium was superior to salmeterol in reducing exacer-
bations, but the difference was small (Evidence A) [53] .
 In 2008, a meta-analysis of 17 randomized trials re-
ported an increased risk of cardiovascular events from 
using anticholinergics  [54] . In contrast, the UPLIFT trial 
 [52] did not show an increased risk. An FDA-expert pan-
el discussed these contradictory findings and concluded, 
based on methodological considerations, that the current 
data do not support the supposition that the use of tiotro-
pium is accompanied by an increased risk of cardiovas-
cular events  [55] .
  2 Agonists 
 Sympathomimetic bronchodilators protect against 
bronchospasm induced by various stimuli, reduce static 
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and dynamic hyperinflation and improve dyspnea, even 
if FEV 1 remains unchanged. The effects of short-acting   2 
agonists (SABA: salbutamol, terbutaline or formoterol) 
disappear within 4–6 h. SABAs are used as rescue medi-
cation and patients are allowed to increase the number of 
puffs and to shorten the interval between puffs from MDI 
or DPI, provided it is for a short period of time (3–4 h).
 The effects of long-acting inhaled   2 agonists (LABA: 
salmeterol and formoterol) are maintained over 12 h or 
even for up to 24 h by the ultralong-acting bronchodila-
tor, indacaterol, which needs to be administered only 
once daily  [56, 57] .
 In the TORCH trial studying the combined effect of 
salmeterol and fluticasone  [58] , the lung functions, num-
ber of exacerbations and average change in clinical scores 
over 3 years was significantly better in the combination-
therapy group than in the group treated with salmeterol 
only, fluticasone only or placebo. The side effects of   2 
agonists are proportional to their dosage and consist 
mostly of tremor, some degree of tachycardia and hypo-
kalemia especially when prescribed with diuretics.
 Phosphodiesterase Inhibitors 
 Theophylline is a xanthine derivate and acts as a non-
selective phosphodiesterase inhibitor. It has a modest 
bronchodilator effect in stable COPD (Evidence A)  [59] 
and shows various physiological actions, the significance 
of which is disputed. Theophylline is metabolized by cy-
tochrome P450-dependent mixed-function oxidases and 
many physiological variables and drugs modify its me-
tabolism. It is less effective than and not as well tolerated 
as inhaled long-acting bronchodilators, and is therefore 
not recommended as a first-line drug.
 Roflumilast is a phosphodiesterase-4 inhibitor and 
has recently been approved for use in GOLD stage III and 
IV COPD. Its principal action is to reduce inflammation 
by inhibiting the breakdown of intracellular cyclic ade-
nosine monophosphate. Roflumilast reduces moderate 
and severe exacerbations by 15–20% in patients with 
chronic bronchitis, severe to very severe COPD and a his-
tory of exacerbations (Evidence A)  [60, 61] . It is a once-
daily medication and slight improvements in FEV 1 are 
seen when it is added to long-acting bronchodilators. 
There are no comparison or add-on studies of roflumilast 
and inhaled corticosteroids (ICS). Patients have to be in-
formed about the potential side effects i.e. diarrhea and 
weight loss.
 Glucocorticosteroids 
 When considering the position of glucocorticoste-
roids in the management of COPD, their role during ex-
acerbations and during stable phases (steroid trial) should 
be distinguished. The effects of glucocorticosteroids on 
airway inflammation in COPD are much less pronounced 
than in asthma. Based on the lack of any evidence of a 
long-term beneficial effect of chronic oral glucocorticoid 
therapy in subjects with confirmed COPD and a large 
body of evidence on the long-term adverse effects of this 
treatment, chronic treatment with oral glucocorticoste-
roids should be avoided in COPD (Evidence A) [62–66] . 
A short course of oral corticosteroids is not a reliable pre-
dictor of the long-term response to inhaled glucocortico-
steroids in COPD, but can be helpful to differentiate 
COPD from bronchial asthma. The effect of a steroid tri-
al should be objectively assessed based on FEV 1 measure-
ments during a stable phase of the disease (at least 6 weeks 
after an exacerbation)  [67] .  However, a short course of 
oral corticosteroids is indicated in COPD exacerbations.
 Inhaled Glucocorticosteroids 
 The dose-response relationships and long-term safety 
of ICS in COPD are not known. Only moderate to high 
doses have been used in long-term clinical trials. The ef-
fects of ICS on pulmonary and systemic inflammation in 
patients with COPD are controversial. ICS, particularly 
in fixed combinations with LABA, are overused and their 
role should be limited to specific indications. Regular 
treatment with ICS does not modify the long-term de-
cline of FEV 1 or mortality in patients with COPD (Evi-
dence A). ICS improve symptoms, lung function and 
quality of life, and reduce the frequency of exacerbations 
in COPD patients with an FEV 1  ! 60% pred. (Evidence A). 
ICS in combination with a LABA are more effective than 
the individual components in improving lung function, 
health status and reducing exacerbations when the COPD 
is moderate (Evidence B) to very severe (Evidence A). In 
summary, the use of ICS is recommended in severe and 
very severe COPD and in GOLD stage II COPD with an 
FEV 1  ! 60% pred. and frequent exacerbations. In the 
TORCH trial, combination therapy was associated with 
an increased risk of pneumonia, but not with overall 
mortality (Evidence A)  [58, 68–74] .
 The addition of a LABA/ICS combination to tiotro-
pium is frequently used in severe to very severe COPD. 
This triple combination improves lung function and 
quality of life and may further reduce exacerbations com-
pared to tiotropium monotherapy or LABA/ICS dual 
therapy  [75, 76] .
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 Antibiotics 
 The use of antibiotics in stable disease (i.e. outside of 
exacerbations) is not recommended. A recent trial of dai-
ly azithromycin, a macrolide antibiotic, showed efficacy 
on exacerbation end points  [77] . However, general use is 
not recommended until further studies confirm effec-
tiveness and exclude relevant long-term side effects.
 Mucolytics 
 A review article has recently been published about the 
effects of mucoactive therapy in COPD  [78] . Most trials 
have been performed with N-acetylcysteine or carbocys-
teine. Overall, the authors found a significant reduction 
in exacerbations and in the number of days with disabil-
ity. Mucolytics were well tolerated and the number of ad-
verse events was lower than with placebo. However, in the 
largest and best-designed study with N-acetylcysteine in 
523 patients with COPD, the reduction in exacerbations 
was only observed in patients not taking ICS  [79] . The use 
of mucolytics is not generally recommended, but may be 
an option in COPD patients with frequent exacerbations.
 Immunostimulating Agents 
 Immunostimulating agents made from bacterial ex-
tracts represent a class of medications whose potential 
benefit results from a nonspecific stimulation of the im-
mune system.
 A systematic review of the studies on the use of bacte-
rial extracts in COPD patients has shown a reduction in 
the symptoms of COPD exacerbations but no reduction 
of the rate of the exacerbations  [80] .
 Vaccination 
 Influenza Vaccination 
 Influenza vaccination can reduce lower-tract respira-
tory infections that require hospitalization or cause death 
(Evidence A)  [81] . Vaccination does not increase consul-
tations, corticosteroid prescriptions or exacerbations in 
subjects with asthma or COPD  [82, 83] . The strains are 
adjusted annually for appropriate effectiveness and 
should be given each year in autumn (or possibly twice, 
in autumn and winter).
 Pneumococcal Vaccine 
 The 23-valent pneumococcal polysaccharide vaccine 
protects against invasive pneumococcal disease, such as 
bacteremia and meningitis, but does not reduce all-cause 
pneumonia. In a small study, a decreased rate of pneumo-
nia was found only in younger people ( ! 65 years) and in 
those with severe airflow obstruction (FEV 1  ! 40%)  [84] . 
In spite of this weak evidence, the 23-valent pneumococ-
cal polysaccharide vaccine is recommended for all suffer-
ers of chronic lung disease (Evidence B). Results on the 
effect of a conjugated 13-valent pneumococcal vaccine in 
adults are not available for the time being.
 Oxygen Therapy 
 It has been shown that the survival of patients with 
chronic respiratory failure due to COPD is improved by 
long-term oxygen administration ( 1 15 h per day) (Evi-
dence B)  [85–87] .
 Long-term oxygen therapy  [88]  is indicated if the PaO 2 
is:
 – at or below 7.3 kPa (55 mm Hg) with or without hyper-
capnia confirmed twice over a 3-week period (Evi-
dence B) 
 – between 7.3 kPa (55 mm Hg) and 8.0 kPa (59 mm Hg), 
if there is evidence of pulmonary hypertension or 
polycythemia (hematocrit  1 55%) (Evidence D). 
Long-term oxygen therapy may be considered in:
 – situative hypoxemia, i.e. hypoxemia ( ! 90% satura-
tion) during sleep or during exercise. 
 The primary goal of oxygen therapy is to increase the 
baseline arterial partial pressure (PaO 2 ) to at least 8.0 kPa 
(60 mm Hg) or to achieve arterial oxygen saturation equal 
to or above 90%. Smoking cessation is a requirement for 
long-term oxygen therapy. The prescription of oxygen 
should always include the source of supplemental oxygen 
(gas or liquid), the method of delivery (via nasal cannula 
or transtracheal), the duration of use ( 1 15 h or, if possible, 
24 h per day) and the flow rate at rest, during exercise and 
sleep. Oxygen given during exercise may increase walking 
distance and endurance most likely by optimizing oxygen 
delivery to the tissues and its utilization by muscles. How-
ever, there are no data to suggest that long-term oxygen 
therapy changes exercise capacity per se.
 In the absence of symptoms of sleep apnea, there is no 
indication for specific sleep studies.
 Alpha-1-Antitrypsin Replacement 
 Intravenous replacement with   1 -antitrypsin (AAT) 
increases AAT levels and antielastase activity in serum 
and in bronchoalveolar lavage fluid  [15] . Uncontrolled 
trials have shown positive effects with augmentation 
therapy in COPD patients with AAT deficiency. Two 
small, randomized, double-blind, placebo-controlled tri-
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als have investigated the efficacy of intravenous AAT 
augmentation therapy on emphysema progression using 
CT densitometry  [89, 90] . Data from these similar trials, 
the 2-center Danish-Dutch study (n = 54) and the 3-cen-
ter EXACTLE study (n = 65), have been pooled to in-
crease the statistical power  [91] . All subjects, i.e. 60 under 
replacement and 59 in the placebo group, were assessed 
by a CT scan at baseline and after treatment, with a mean 
follow-up of approximately 2.5 years. The combined data, 
as analyzed by one of four analytical methods, showed a 
significantly reduced decline in lung density. However, 
clinical end points (decline of FEV 1 , exacerbation rate 
and quality of life) did not demonstrate statistical differ-
ences. Due to this and to a lack of accepted criteria to as-
sess the efficiency of this costly treatment, a recommen-
dation for AAT replacement cannot be given.
 Ventilatory Support 
 Noninvasive ventilation in combination with long-
term oxygen therapy may be used in a selected subset of 
patients, particularly in those with pronounced daytime 
hypercapnia. In patients with both COPD and obstruc-
tive sleep apnea, there are clear benefits from continuous 
positive airway pressure (CPAP) in relation to both sur-
vival and the risk of hospital admission  [92, 93] .
 Pulmonary Rehabilitation, Psychological Support and 
Nutrition 
 Rehabilitation 
 Exercise capacity and the level of physical activity are 
strong prognostic factors in COPD. Pulmonary rehabili-
tation and maintenance of physical activity have the po-
tential to improve exercise tolerance, to decrease dyspnea 
and anxiety and to reduce the number of hospitalizations 
(Evidence A) [94, 95] . Comprehensive pulmonary reha-
bilitation includes patient education, instruction for self-
management (action plans), nutritional counseling and 
exercise training. The type of exercise (stair climbing, 
walking, treadmill and bicycle ergometer) may vary and 
is best determined by patient preference. Interval exercise 
training is usually better tolerated by patients. Whether 
pulmonary rehabilitation is conducted in an inpatient or 
outpatient setting depends on local availability and a pa-
tient’s preference and comorbidity. Pulmonary rehabili-
tation is also effective soon after exacerbations  [96] . Co-
morbidities are not a contraindication for pulmonary re-
habilitation  [97] . The benefit in exercise performance and 
quality of life is maintained if patients follow a regular 
exercise program at home  [98] . The routine use of respi-
ratory muscle training cannot be recommended, but in-
dividual patients may benefit from this.
 Psychological Support 
 COPD is a progressive disease that will eventually se-
verely impair the patient’s quality of life. Even with the 
best care, shortness of breath, once it starts occurring 
during daily activities, profoundly modifies family life, 
sexuality and social interaction. The patient becomes 
more isolated, dependent and depressed. This complex 
burden of suffering can be overwhelming, and a patient’s 
coping mechanisms may be insufficient. The prevalence 
of anxiety and depression is higher in certain COPD pa-
tients and is associated with dyspnea and a reduced qual-
ity of life  [99–101] . Exercise training and antidepressant 
drugs are often effective in ameliorating dyspnea and 
anxiety  [102] . Pulmonary rehabilitation may decrease 
psychosocial morbidity even without specific psycholog-
ical interventions  [103] .
 Nutrition 
 Weight loss is a common feature in patients with ad-
vanced COPD. The clinical importance of weight loss, 
particularly of fat-free mass, and its adverse effects on 
physical performance and quality of life have been dem-
onstrated  [104] . Moreover, a low BMI is an independent 
predictor for increased mortality  [105] . Although nutri-
tional support in these patients seems logical, controlled 
trials have not shown significant effects of weight gain on 
lung function or exercise capacity in patients with stable 
COPD  [106] . Supplementation may, however, improve the 
outcome of training in some patients  [107] .
 Invasive Interventions 
 Lung Volume Reduction Surgery 
 Bullectomy, i.e. the removal of large bulla that compress 
the adjacent lung structures, is a well-established surgical 
procedure and can be performed thoracoscopically. It is 
effective in reducing dyspnea and improving lung func-
tion  [108, 109] . Lung volume reduction surgery (LVRS) re-
duces emphysematous parts of the lung to reduce hyper-
inflation. It is a palliative procedure which not only im-
proves pulmonary function and exercise capacity in 
selected patients with severe hyperinflation, but has a ma-
jor positive impact on quality of life for several years  [110, 
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111] . Patients with heterogeneous types of emphysema and 
low exercise capacity have the greatest improvement in 
pulmonary function after LVRS  [112] , but patients with 
homogeneous emphysema may also experience signifi-
cantly better health status and lung function compared to 
with usual medical care – when high-risk candidates with 
an extremely low FEV 1 and a homogeneous emphysema or 
a diffusing capacity of  ! 20% pred. were excluded.
 Bronchoscopic Lung Volume Reduction 
 A range of different techniques such as endobronchial 
valves, coils, airway bypass, thermal vapor ablation and 
biological sealants have been employed in both homoge-
neous as well as heterogeneous types of emphysema. 
Carefully selected patients with very severe COPD may 
benefit from bronchoscopic lung volume reduction  [113] . 
However, the currently available data on the efficacy and 
safety of different types of bronchoscopic lung volume 
reduction procedures are not conclusive and further data 
is therefore needed.
 Lung Transplantation 
 The decision to proceed with lung transplantation for 
severe COPD is complex. There is plenty of evidence sug-
gesting that functional capacity is improved following the 
procedure, but the presence of a survival benefit is less 
clear. It is important to define disease severity as precisely 
as possible in order to determine which patients have the 
most urgent need for lung transplantation and are likely to 
have the longest survival afterwards. Transplantation is 
usually deferred until the BODE index is 7 or higher, the 
FEV 1 is  ! 20% pred., the diffusing capacity for carbon 
monoxide is  ! 20% pred. or the clinical course becomes 
more aggressive with life-threatening exacerbations. Since 
many patients with advanced COPD are older and affected 
by comorbidities, the selection of suitable transplant can-
didates is a particular challenge. Contraindications for 
lung transplantation are malignancies, renal or liver fail-
ure, drug abuse and emotional instability. It is essential to 
refer possible lung transplantation candidates for evalua-
tion to a lung transplant center early enough  [114–116] .
 Exacerbation of COPD 
 Definition, Impact, Severity and Etiology 
 An exacerbation, as defined by the GOLD, is ‘an event 
in the natural course of the disease characterized by a 
change in the patient’s baseline dyspnoea, cough and/or 
sputum that is beyond normal day to day variation, is acute 
in onset and may warrant a change in regular medication 
in a patient with underlying COPD’  [117] . Exacerbations in 
COPD are characterized by a broad variation in clinical 
presentation and are triggered by several factors.
 It has been recognized that there is a subgroup of 
COPD patients who experience frequent exacerbations 
( 6 2 per year). Recurrent exacerbations have a strong neg-
ative impact on quality of life, often lead to hospitaliza-
tion and are associated with higher rates of morbidity and 
mortality in COPD. The association of several clinical 
features with frequent exacerbations has been demon-
strated, including a higher degree of airway obstruction, 
an advanced GOLD stage or BODE category, the presence 
of chronic cough and sputum production, advanced age 
and clinical depression.
 The current American Thoracic Society and European 
Respiratory Society guidelines provide a descriptive 
means of defining the severity of exacerbations  [23] . The 
classification of exacerbation severity is thereby defined 
by the necessary extent of the acute medical intervention. 
Exacerbations are divided into 3 categories, level I with 
treatment at home, level II requiring hospitalization and 
level III requiring ICU admission for respiratory failure, 
respectively. The classification of exacerbations into 
types I–III according to the criteria by Anthonisen et al. 
 [118] does not reflect disease severity but is often used to 
estimate the likelihood of a of COPD exacerbation having 
a bacterial cause.
 Although less than 50% of exacerbations have a bacte-
rial cause, the presence of bacteria detected by sputum 
examination varied between 17 and 87% in certain inves-
tigations. In recognition of these diagnostic limitations, 
sputum cultures should not be performed during most 
exacerbations. Only selected cases, e.g. patients with 
FEV 1  ! 30% pred., extensive bronchiectasis, prior evi-
dence of Gram-negative rods or contemporary or previ-
ous antibiotic therapy warrant sputum cultures at exac-
erbation (Evidence C).
 Therapy 
 Pharmacological Therapy 
 Bronchodilators, systemic corticosteroids, antibiotic 
agents, oxygen and noninvasive positive-pressure venti-
lation are the most common therapeutic measures in ex-
acerbations of COPD.
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 Bronchodilators 
 Short-acting   2 agonists are the cornerstone of the 
treatment of exacerbations of COPD (Evidence D). The 
addition of an anticholinergic is generally recommended 
(Evidence D).
 Glucocorticoids 
 Several randomized, controlled trials suggest that sys-
temic glucocorticoids in COPD exacerbations accelerate 
the recovery of FEV 1 , decrease the length of hospital stay 
and improve clinical outcome (Evidence A)  [119] . The 
strongest treatment effect of steroids occurs probably 
within the first 72 h and it levels off thereafter, suggesting 
a lack of benefit beyond 5 days of treatment. Despite a lack 
of well-designed randomized trials evaluating the most 
effective steroid dose, we recommend oral steroids be ad-
ministered once daily in doses of 20 to 60 mg of predni-
sone  [120] for 5–15 days (Evidence C).
 Antibiotics 
 The role of antibiotics in the treatment of COPD exac-
erbations is much less prominent than the role of steroids 
 [121, 122] . Viral infections are known to be the most com-
mon cause of acute exacerbations in COPD. Paradoxi-
cally, viral exacerbations were associated with more se-
vere exacerbations and more prolonged symptom recov-
ery than nonviral exacerbations. However, there is 
currently no reliable method to clearly distinguish bacte-
rial exacerbations from those due to other etiologies. 
General recommendations for antibiotic use are not uni-
form and are often based on less-evaluated clinical pa-
rameters. Taking the risk of antibiotic overuse into ac-
count, routine antibiotic use has to be examined criti-
cally in outpatient exacerbations which often occur with 
a high spontaneous recovery rate (Evidence C). Antibiot-
ics may be prescribed to patients who have 3 cardinal 
symptoms: an increase in dyspnea, sputum volume and 
sputum purulence (Evidence B), and also to patients with 
severe exacerbation who are admitted to an ICU (Evi-
dence A)  [123] . The determination of serum procalcito-
nin was shown to reduce the use of antibiotics in COPD 
exacerbations and may be of value in the decision to use 
antibiotics (Evidence A)  [124] . If antibiotics are deemed 
needed, a short treatment course of  ^  5 days is preferred, 
as these have an outcome equal to a conventional treat-
ment with antibiotics of 7–10 days (Evidence C)  [125] . 
Longer courses of antibiotics should be considered for pa-
tients with more severe exacerbations requiring a hospital 
admission or ICU stay and those with proven coloniza-
tion or infection with Gram-negative rods.
 The effectiveness of older first-line antibiotics (amox-
icillin, ampicillin and doxycyclin) and the newer broad-
spectrum second-line antibiotics (amoxicillin/clavulanic 
acid, 2nd and 3rd generation cephalosporins and quino-
lones) is comparable with regard to mortality, microbial 
outcome and the rate of adverse events (Evidence C). Sec-
ond-line agents might present a small benefit in patients 
with more severe disease or more common exacerbations 
(Evidence C). Currently, the choice of antibiotic agent 
should therefore be guided by a recent history of antibi-
otic use and local microbial resistance patterns.
 Oxygen 
 Oxygen therapy should be considered in the treatment 
of severe COPD exacerbations (Evidence D). Oxygen 
should be titrated to provide adequate levels of oxygen-
ation (PaO 2  1 8.0 kPa or SaO 2  1 90%). It is reasonable to 
assess arterial blood gases within 30–60 min after the in-
stitution of oxygen therapy to exclude significant CO 2 re-
tention.
 Nonpharmacological Therapy 
 Several randomized trials and meta-analyses indicat-
ed that noninvasive positive pressure ventilation im-
proves important clinical outcomes, such as intubation 
rate, treatment failure and inhospital mortality in pa-
tients with an acute exacerbation complicated by hyper-
capnic acidosis (Evidence A)  [126] .
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